Reply to Drs. Olanow and Rascol.
Ahlskog
J Eric
JE
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. eahlskog@mayo.edu
Uitti
Ryan J
RJ
D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D003627:Data Interpretation, Statistical; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000592:standards*; D010300:Parkinson Disease / Q000188:drug therapy*; D015990:Placebo Effect; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*
D015415:Biomarkers; D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline